Here's What You Need to Know Ahead of Johnson & Johnson's Earnings Report
Johnson & Johnson has been on a roll. Thanks to a steady string of successful new drug launches, the company has beat analysts' earnings estimates in each of the past four quarters.
When Johnson reports earnings on July 15, investors will learn whether fast growth continued for key drugs including Zytiga, Xarelto, and Olysio.
In the following slideshow, you'll see what has been driving Johnson's success this past year and what you should be looking for in Johnson's release.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
The article Here's What You Need to Know Ahead of Johnson & Johnson's Earnings Report originally appeared on Fool.com.Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.